(NASDAQ: RAPP) Rapport Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.64%.
Rapport Therapeutics's earnings in 2025 is -$78,307,000.On average, 3 Wall Street analysts forecast RAPP's earnings for 2025 to be -$128,467,458, with the lowest RAPP earnings forecast at -$142,336,104, and the highest RAPP earnings forecast at -$118,613,420. On average, 3 Wall Street analysts forecast RAPP's earnings for 2026 to be -$154,865,331, with the lowest RAPP earnings forecast at -$159,854,394, and the highest RAPP earnings forecast at -$151,460,214.
In 2027, RAPP is forecast to generate -$202,555,225 in earnings, with the lowest earnings forecast at -$202,555,225 and the highest earnings forecast at -$202,555,225.